Publications
A selection of key publications by the founders of ProFibrix related to fibrinogen
Help for the Haemostasis Market
Jaap Koopman and Jan Ohrstrom at Profibrix examine how haemostats based on fibrin
are able to harness the natural blood clotting system to treat and prevent excessive bleeding > Read More
Recombinant Bbeta Arg14His fibrinogen implies participation of N-terminus of Bbeta chain in desA fibrin polymerization.
Moen JL, Gorkun OV, Weisel JW, Lord ST. Blood 2003; 102: 2466-2471.
Aberrant fibrin formation and cross-linking of fibrinogen Nieuwegein, a variant with a shortened Aalpha-chain, alters endothelial capillary tube formation.
Collen A, Maas A, Kooistra T, Lupu F, Grimbergen J, Haas FJ, Biesma DH, Koolwijk P, Koopman J, van Hinsbergh VW. Blood 2001; 97: 973-980.
Insight from studies with recombinant fibrinogens.
Lord ST, Gorkun OV. Annals of the New York Academy of Sciences 2001; 936: 101-116.
Fibrinogen Ales: a homozygous case of dysfibrinogenemia (gamma-Asp (330)® Val) characterized by a defective fibrin polymerization site “a”.
Lounes KC, Soria C, Mirshahi SS, Desvignes P, Mirshahi M, Bertrand O, Bonnet P, Koopman J, Soria J. Blood 2000; 96: 3473-3479.
Decreased lateral aggregation of a variant recombinant fibrinogen provides insight into the polymerization mechanism.
Mullin JL, Gorkun OV, Lord ST. Biochemistry 2000; 39: 9843-8849.
Recombinant fibrinogen studies reveal that thrombin speceficity dictates order of fibrinopeptide release.
Mullin JL, Gorkun OV, Binnie CG, Lord ST. Journal of Biological Chemistry 2000; 275: 25239- 25246.
Fibrinogen structure and thrombosis.
Koopman J, de Maat M.
In: A.I. Schafer, ed. Molecular mechanisms of hypercoagulable states. Austin, Texas: Landes Bioscience, 1997: 125-140.
The conversion of fibrinogen to fibrin: recombinant fibrinogen typifies plasma fibrinogen.
Gorkun OV, Veklich YI, Weisel JW, Lord ST. Blood 1997; 89: 4407-4414.
Strategy for recombinant multichain protein synthesis: fibrinogen beta-chain variants as thrombin substrates.
Lord ST, Strickland E, Jayjock E. Biochemistry 1996; 35: 2342-2348.
Hereditary variants of human fibrinogen.
Koopman J, Haverkate F. In: A.L. Bloom, C.D. Forbes, D.P. Thomas, E.G.D. Tuddenham, eds. Haemostasis and Thrombosis, third edition. London: Churchill Livingstone, 1994: 515-529.
The molecular basis for fibrinogen Dusart (Aa 554 Arg à Cys) and its association with abnormal fibrin polymerization and thrombophilia.
Koopman J, Haverkate F, Grimbergen J, Lord ST, Mosesson MW, DiOrio JP, Siebenlist K, Legrand C, Soria J, Soria C, Caen JP. Journal of Clinical Investigations 1993; 91: 1637-1642.
Purification and characterization of recombinant human fibrinogen.
Lord ST, Binnie CG, Hettasch JM, Strickland E. Blood Coagulation & Fibrinolysis 1993; 4: 55-59.
The molecular basis of fibrinogen Naples associated with defective thrombin binding and thrombophilia: Homozygous substitution of Bb 68 Ala à Thr.
Koopman J, Haverkate F, Lord ST, Grimbergen J, Mannucci PM. Journal of Clinical Investigations 1992; 90: 238-244.
Abnormal fibrinogens IJmuiden (Bb Arg14 à Cys) and Nijmegen (Bb Arg44 à Cys) form disulfide-linked fibrinogen-albumin complexes.
Koopman J, Haverkate F, Grimbergen J, Engesser L, Novakova I, Kerst A, Lord ST. Proceedings of the National Academy of Sciences, U.S.A. 1992; 89: 3478-3482.
Fibrinogen Marburg: A homozygous case of dysfibrinogenemia, lacking amino acids Aa 461-610 (Lys 461 AAA à Stop TAA).
Koopman J, Haverkate F, Grimbergen J, Egbring R, Lord ST. Blood 1992; 80: 1972-1979.
A congenitally abnormal fibrinogen (Vlissingen) with a six-base deletion in the g-chain gene, causing defective calcium binding and impaired fibrin polymerization.
Koopman J, Haverkate F, Briët E, Lord ST. Journal of Biological Chemistry 1991; 265: 13456-13461.
